Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL487587 | 0.92 | PDK1 (0.49) | PDK1MEN1KMT2ASMN1; SMN2EP300 | |
| SCHEMBL10289645 | 0.86 | HIF1A (0.50) | MEN1KMT2ANPC1TP53HPGD | |
| SCHEMBL487607 | 0.81 | HIF1A (0.48) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL487288 | 0.73 | NPC1 (0.57) | KMT2ANPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL487466 | 0.72 | HSP90AA1 (0.59) | PDK1 | |
| SCHEMBL15004588 | 0.68 | HSP90AA1 (0.38) | MEN1KMT2ATP53HPGDSMN1; SMN2 | |
| SCHEMBL487745 | 0.68 | MAPT (0.43) | MEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL30277679 | 0.67 | PTGES (0.49) | PDK1MEN1KMT2A | |
| SCHEMBL15004568 | 0.67 | HSP90AA1 (0.37) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15004590 | 0.66 | ALDH1A1 (0.39) | MEN1KMT2ANPC1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106057-B2 | Dihydroxyphenyl isoindolylmethanones | ASTEX THERAPEUTICS, LTD. (GB) | 2012-01-31 | — | — | US | disclosed |
| US-20100286167-A1 | DIHYDROXYPHENYL ISOINDOLYLMETHANONES | ASTEX THERAPEUTICS LTD. (GB) | 2010-11-11 | — | — | US | disclosed |
| US-7754725-B2 | Dihydroxyphenyl isoindolymethanones | ASTEX THERAPEUTICS LTD. (GB) | 2010-07-13 | — | — | US | disclosed |
| US-20080306054-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | ASTEX THERAPEUTICS, LTD. (GB) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286167-A1 | DIHYDROXYPHENYL ISOINDOLYLMETHANONES | HSP90AA1, HSP90AB1, HSP90AB2P | PDK1 1212/4885MEN1 4364/4885KMT2A 2907/4885 |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | HSP90AB2P, HSP90AA1, HSP90AB1 | PDK1 449/4885MEN1 4105/4885KMT2A 3703/4885 |
| US-20080306054-A1 | Pharmaceutical Compounds | HSP90AB1, HSP90AA1, HSP90AB2P | PDK1 1687/4885MEN1 2045/4885KMT2A 4660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.